Trince

Ottergemsesteenweg-Zuid 731

9000 Gent

BE

Trince

Foundation date

17/09/2021

Sector

#Supplier & Engineering

Subsector

Trince, a spin-off company from UGent is dedicated to delivering molecules into cells, both in vitro and ex vivo. Its LumiPore transfection platform combines laser exposure and nanoparticles to transiently permeabilize cell membranes. It can be used to deliver a wide variety of effector molecules into virtually any cell type, including hard-to-transfect cells. The high-throughput technology ensures efficient and gentle transfection, maximizing the therapeutic quality of the final cell product.

Upcoming events

Latest news

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    7 hours ago

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022